Patients were categorized into three risk groups: 1) men with N1 disease (N1), 2) men without N0, but who had either pT3 stage, RP Gleason score 8, lymphovascular invasion or tertiary Gleason 5 pattern (N0 high-risk [HR]) and 3) men with no high-risk features at RP (N0IR). Decipher scores were obtained from 263 RP specimens and 25 matching biopsy specimens. Fisher's exact test was used to compare the difference in patient risk groups. Logistic regression analysis was used to evaluate performance of Decipher for prediction of LNI. Discrimination of the Partin tables (2%) and combined model of Partin tables (2%) and Decipher (>0.6) was assessed using c-index. Concordance of biopsy and RP Decipher (low-and intermediate-vs high-risk) was also assessed.
INTRODUCTION AND OBJECTIVES: There has been increasing emphasis on active surveillance to limit overtreatment of prostate cancer (PC). However, the actual effect that such emphasis has on the selection of patients for radical prostatectomy (RP) has not been well studied. In this study, we investigated the trends in PC pathology at yearly intervals over the past decade to verify any changes in the RP population.
METHODS: We retrospectively reviewed information from 1034 patients who underwent open RP between October 2004 and August 2015 by a single surgeon at a high-volume tertiary care center. Information was cataloged into one-year intervals. Chi-squared, Fisher's Exact test, ANOVA, and Kruskal-Wallis test were used for data analysis.
RESULTS: There was significant in-group differences among the one-year intervals regarding pathological Gleason score (p<0.01), pathological staging (p<0.04), extracapsular extension (p <0.001), and positive margins (p¼0.0001), with trends in increasing percentages of prostate glands with adverse pathological features over time. There was significant in-group differences in Gleason upgrading (p<0.01), with decreasing pathology upgrading over time. There was significant ingroup differences in pre-RP D'Amico risk stratification over time (p<0.01). The percent of patients with pre-RP low-risk D'Amico pathology decreased from 42.9% in 2004 to 24.3% in 2009, increased to 50.9% between 2009 and 2011, then decreased again to 27.8% from 2011 to 2015. There were no significant in-group differences in age, race, or seminal vesicle invasion.
CONCLUSIONS: Over the last 10 years, we have increasingly targeted RP to patients with adverse pathology who have greater need for treatment while also reducing Gleason upgrading at RP. Our results indicate decreasing overtreatment and validate the effect that active surveillance emphasis has on changing the population undergoing RP. 
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INTRODUCTION AND OBJECTIVES:
Since high-risk prostate cancer is an extremely heterogeneous disease, it is necessary to further stratify this group of patients. The aim of the present study was to substratify surgically treated patients with high-risk prostate cancer according to combination of accepted risk factors.
METHODS: We identified 239 consecutive patients with NCCN high-risk prostate cancer treated with radical prostatectomy and pelvic lymph node dissection between March 2000 and December 2015 at Wakayama Medical University Hospital. Probabilities of specimenconfined disease (SCD; ¼pT3aN0 and RM0) and biochemical recurrence (BCR) were examined with preoperative risk factors (PSA cT stage, biopsy Gleason score [GS]) using multivariable logistic regression and Cox proportional hazard models, respectively. Patients were then classified according to the combination of preoperative risk factors (PSA > 20ng/mL, cT3a, biopsy GS ¼8) and probability of SCD and BCR-free survival were compared among groups.
RESULTS: SCD was observed in 139 patients (58.2%). Fiveyear BCR-free survival rate was 61.7%. Multivariable analyses identified PSA as the only independent predictor of SCD and BCR after adjustment for age and type of surgery (Table) . Based on the BCR-free survival rates for seven subgroups according to the combination of three preoperative risk factors, simple model with three subgroups were constructed, i.e., group 1: risk factor(s) other than PSA > 20ngmL; group 2: PSA > 20ng/ mL only; group 3: PSA ¼ 20ng/mL and other risk factor(s). BCR-free survival rates were significantly different among three groups (p < 0.01, Figure) . In addition, probabilities of SCD were also significantly different among groups (64.2% vs. 51.1% vs. 34.5%, p<0.01).
CONCLUSIONS: This study identified PSA as the most important preoperative risk factor in patients with high-risk prostate cancer and generated simple prognostic model according to PSAbased combination of three risk factors. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e849
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